drugset
drugset / Trial / NCT01564563

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation

NCT01564563 ↗

Phase 2 Terminated 11 enrolled Novo Nordisk A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the efficacy of activated recombinant human factor VII in treatment of bleeding in patients having undergone a hematopoietic stem cell transplantation.

Timeline

Start
2002-06-28
Primary completion
2003-10-27
Completion
2003-10-27

Drugs

EvaluationDrugModalityDoseRoute
Subject eptacog alfa (activated) Protein / enzyme biologic — Intravenous

Indications

acquired coagulation factor deficiency